Latest Regenerative Perinatal News

New Study: Exosome Therapy from Umbilical Cord Stem Cells Shows Early Promise for Osteoarthritis

Researchers are testing whether exosomes from umbilical cord stem cells can safely reduce inflammation and support cartilage repair in osteoarthritis.

New Review Dubs Umbilical Stem Cells “Holy Grail” in Bioengineering and Reconstructive Medicine

New peer-reviewed review argues that Wharton's Jelly derived mesenchymal stem cells offer a novel, non-invasive option for many regenerative therapies.

BioTissue Nabs Vizient Contract to offer Amniotic Allograft Products in the USA

The new agreement enables Vizient members broader access to BioTissue’s amniotic membrane products for diverse clinical applications.

NeuroScientific Chooses Q-Gen for its StemSmart Cell Therapy Platform

The Australian biotech company is preparing for trials and commercialization of its stem cell therapy platform for Crohn's disease, StemSmart.

Stem Cell and Spinal Stimulation Trial for Chronic Spinal Cord Injury

The study will test whether combining umbilical cord stem cells and spinal cord stimulation can safely help people with chronic spinal cord injury.

Stem Cell Trial: Umbilical Cord MSCs to Prevent Lung Disease in Preterm Infants

Researchers will test if umbilical cord stem cell infusions can safely reduce lung disease in extremely premature infants.

New Trial: Umbilical Cord Mesenchymal Stem Cells for Lupus

The trial will investigate whether umbilical cord stem cell therapy can calm the autoimmune condition.

New trial: Umbilical-derived stem cells for knee cartilage

This small German biotech company is joining the knee OA stem cell race.

New Study: Intrathecal Umbilical Stem Cells + Transcutaneous Stimulation for Spinal Cord Injury

The neurorehabilitation hospital in Spain will investigate if allogeneic umbilical-derived stem cell therapy can help enhance recovery.

New York Blood Center Enterprises and Human Life CORD sign agreement to expand umbilical-derived mesenchymal stem cell manufacturing in the West

Leveraging NYBCe's CDMO subsidiary, the companies plan on bridging the gap between Asian and American manufacturing standards. This collaboration seeks to tackle industry-wide GMP capacity challenges, making advanced cell therapies more accessible worldwide
x
Subscribe
Subscribe

Stay updated on Regenerative Medicine

Subscribe